We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Rapid Test Detects Both HIV and TB in Blood Sample

By LabMedica International staff writers
Posted on 21 Nov 2023

HIV and tuberculosis (TB) frequently occur together, posing a significant health challenge. More...

HIV weakens the immune system, increasing susceptibility to infections like TB. Indeed, individuals with HIV are at the greatest risk of developing TB. Traditional TB diagnosis involves culturing sputum, saliva, and mucus mix, but this process is time-consuming and often not feasible for urgent treatment needs. Additionally, sputum collection is not viable for HIV patients due to their compromised immune systems. To fill this diagnostic gap, researchers have developed a rapid, dual-detection blood test that can identify both HIV and TB simultaneously using just a small blood sample.

This breakthrough blood test, developed by researchers at Tulane University (New Orleans, LA, USA), not only identifies HIV and TB but also measures their respective viral and bacterial loads. Requiring only about 200 microliters of blood – a mere few drops – the test bypasses the need for sputum samples, making it particularly useful for HIV patients. It operates by targeting specific HIV and TB antigens present in the blood, utilizing mass spectrometry for precise measurement of viral and bacterial quantities.

A key benefit of this novel test is its ability to monitor the levels of both HIV and TB during a patient's treatment. This real-time tracking is crucial in managing immune reconstitution inflammatory syndrome (IRIS), a condition where treating one infection may exacerbate the other. The test's rapid results allow for timely adjustments in treatment strategies, enhancing patient outcomes. Such tests are especially critical in developing countries, where TB is more prevalent and access to diagnostic resources is limited. The researchers are optimistic about progressing from their initial pilot study to clinical trials and are aiming for FDA approval of the test.

“For HIV patients, their immune system is very weak, and once they are infected, they can’t confront the bacteria very well, so that’s why there is this urgent need to bring a blood-based TB tests to them,” said Tony Hu at Tulane University School of Medicine who led the research. “For the TB-infected patients, they worry, ‘Why did I get TB? Is it because I have HIV?’ So, this is a multiplex detection to cover both pathogens.”

Related Links:
Tulane University


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.